DaVita Labs appoints vp and general manager

Chronic kidney disease laboratory hires Leslie Mirani

DaVita Labs, a specialist laboratory focused on chronic kidney disease, has appointed Leslie Mirani as vice president and general manager.

Mirani brings to DaVita Labs more than 25 years’ experience in commercial sales and marketing – primarily renal-focused – in the pharmaceutical industry. She previously worked for Human Genome Sciences as an immunology sales director and as vice president for Amgen’s nephrology business unit for 18 years.

DaVita Labs has 86,700ft2 dedicated to its clinical diagnostic laboratories between its two locations in Fort Lauderdale and DeLand, Florida, US.

You may also like

Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Manufacturing

Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies

Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
Digital

Autoscribe Informatics’ new Australia office supports business growth

The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Research & Development

Abzena launches EpiScreen 2.0 to assist the development of complex biologics and bioconjugates

The updated platform delivers an advanced range of immune response measurements, while also providing information on mechanism-of-action and specificity
Research & Development

COVID-19 still a significant risk for the immunocompromised, study finds

AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Manufacturing

Innovation in generics: increased efficiency through peptide API synthesis expertise

Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Subscribe now